Publication

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Postma, M. R., Netea-Maier, R. T., van den Berg, G., Homan, J., Sluiter, W. J., Wagenmakers, M. A., van den Bergh, A. C. M., Wolffenbuttel, B. H. R., Hermus, A. R. M. M. & van Beek, A. P., Apr-2012, In : European Journal of Endocrinology. 166, 4, p. 585-592 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Postma, M. R., Netea-Maier, R. T., van den Berg, G., Homan, J., Sluiter, W. J., Wagenmakers, M. A., van den Bergh, A. C. M., Wolffenbuttel, B. H. R., Hermus, A. R. M. M., & van Beek, A. P. (2012). Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. European Journal of Endocrinology, 166(4), 585-592. https://doi.org/10.1530/EJE-11-0853

Author

Postma, M.R. ; Netea-Maier, R.T. ; van den Berg, G. ; Homan, J. ; Sluiter, W.J. ; Wagenmakers, M.A. ; van den Bergh, A.C.M. ; Wolffenbuttel, B.H.R. ; Hermus, A.R.M.M. ; van Beek, A.P. / Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. In: European Journal of Endocrinology. 2012 ; Vol. 166, No. 4. pp. 585-592.

Harvard

Postma, MR, Netea-Maier, RT, van den Berg, G, Homan, J, Sluiter, WJ, Wagenmakers, MA, van den Bergh, ACM, Wolffenbuttel, BHR, Hermus, ARMM & van Beek, AP 2012, 'Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly', European Journal of Endocrinology, vol. 166, no. 4, pp. 585-592. https://doi.org/10.1530/EJE-11-0853

Standard

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. / Postma, M.R.; Netea-Maier, R.T.; van den Berg, G.; Homan, J.; Sluiter, W.J.; Wagenmakers, M.A.; van den Bergh, A.C.M.; Wolffenbuttel, B.H.R.; Hermus, A.R.M.M.; van Beek, A.P.

In: European Journal of Endocrinology, Vol. 166, No. 4, 04.2012, p. 585-592.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Postma MR, Netea-Maier RT, van den Berg G, Homan J, Sluiter WJ, Wagenmakers MA et al. Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. European Journal of Endocrinology. 2012 Apr;166(4):585-592. https://doi.org/10.1530/EJE-11-0853


BibTeX

@article{fb581368fb4941a0ab2403353015198d,
title = "Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly",
abstract = "Objective: To assess the influence of long-acting somatostatin analogs (SSTA) after initial pituitary surgery on long-term health-related quality of life (HR-QoL) in relation to disease control in patients with acromegaly.Design: This is a cross-sectional study in two tertiary referral centers in The Netherlands.Patients and methods: One hundred and eight patients with acromegaly, in whom transsphenoidal (n = 101, 94%) or transcranial (n = 7, 6%) surgery was performed. Subsequently, 46 (43%) received additional radiotherapy and 41 (38%) were on postoperative treatment with SSTA because of persistent or recurrent disease at the time of study. All subjects filled in standardized questionnaires measuring HR-QoL. Disease control at the time of study was assessed by local IGF1 SDS.Results: IGF1 SDS were slightly higher in patients treated with SSTA in comparison with patients without use of SSTA (0.85 +/- 1.52 vs 0.25 +/- 1.21, P = 0.026), but the percentage of patients with insufficient control (IGF1 SDS >2) was not different (17 vs 9%, P = 0.208). Patients using SSTA reported poorer scores on most subscales of the RAND-36 and the acromegaly QoL and on all subscales of the multidimensional fatigue inventory-20. A subgroup analysis in patients with similar IGF1 levels (SSTA+, n = 26, IGF1 SDS 0.44 +/- 0.72 vs SSTA-, n = 44, IGF1 SDS 0.41 +/- 0.65) revealed worse scores on physical functioning, physical fatigue, reduced activity, vitality, and general health perception across all HR-QoL questionnaires in patients treated with SSTA.Conclusion: QoL is impaired in association with the need for prolonged postoperative therapy by SSTA in patients with acromegaly despite similar IGF1 levels.",
keywords = "GROWTH-FACTOR-I, LONG-TERM, QUESTIONNAIRE ACROQOL, LANREOTIDE TREATMENT, DEPRESSION SCALE, HOSPITAL ANXIETY, DISEASE-ACTIVITY, FOLLOW-UP, HORMONE, RADIOTHERAPY",
author = "M.R. Postma and R.T. Netea-Maier and {van den Berg}, G. and J. Homan and W.J. Sluiter and M.A. Wagenmakers and {van den Bergh}, A.C.M. and B.H.R. Wolffenbuttel and A.R.M.M. Hermus and {van Beek}, A.P.",
year = "2012",
month = apr,
doi = "10.1530/EJE-11-0853",
language = "English",
volume = "166",
pages = "585--592",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BIOSCIENTIFICA LTD",
number = "4",

}

RIS

TY - JOUR

T1 - Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

AU - Postma, M.R.

AU - Netea-Maier, R.T.

AU - van den Berg, G.

AU - Homan, J.

AU - Sluiter, W.J.

AU - Wagenmakers, M.A.

AU - van den Bergh, A.C.M.

AU - Wolffenbuttel, B.H.R.

AU - Hermus, A.R.M.M.

AU - van Beek, A.P.

PY - 2012/4

Y1 - 2012/4

N2 - Objective: To assess the influence of long-acting somatostatin analogs (SSTA) after initial pituitary surgery on long-term health-related quality of life (HR-QoL) in relation to disease control in patients with acromegaly.Design: This is a cross-sectional study in two tertiary referral centers in The Netherlands.Patients and methods: One hundred and eight patients with acromegaly, in whom transsphenoidal (n = 101, 94%) or transcranial (n = 7, 6%) surgery was performed. Subsequently, 46 (43%) received additional radiotherapy and 41 (38%) were on postoperative treatment with SSTA because of persistent or recurrent disease at the time of study. All subjects filled in standardized questionnaires measuring HR-QoL. Disease control at the time of study was assessed by local IGF1 SDS.Results: IGF1 SDS were slightly higher in patients treated with SSTA in comparison with patients without use of SSTA (0.85 +/- 1.52 vs 0.25 +/- 1.21, P = 0.026), but the percentage of patients with insufficient control (IGF1 SDS >2) was not different (17 vs 9%, P = 0.208). Patients using SSTA reported poorer scores on most subscales of the RAND-36 and the acromegaly QoL and on all subscales of the multidimensional fatigue inventory-20. A subgroup analysis in patients with similar IGF1 levels (SSTA+, n = 26, IGF1 SDS 0.44 +/- 0.72 vs SSTA-, n = 44, IGF1 SDS 0.41 +/- 0.65) revealed worse scores on physical functioning, physical fatigue, reduced activity, vitality, and general health perception across all HR-QoL questionnaires in patients treated with SSTA.Conclusion: QoL is impaired in association with the need for prolonged postoperative therapy by SSTA in patients with acromegaly despite similar IGF1 levels.

AB - Objective: To assess the influence of long-acting somatostatin analogs (SSTA) after initial pituitary surgery on long-term health-related quality of life (HR-QoL) in relation to disease control in patients with acromegaly.Design: This is a cross-sectional study in two tertiary referral centers in The Netherlands.Patients and methods: One hundred and eight patients with acromegaly, in whom transsphenoidal (n = 101, 94%) or transcranial (n = 7, 6%) surgery was performed. Subsequently, 46 (43%) received additional radiotherapy and 41 (38%) were on postoperative treatment with SSTA because of persistent or recurrent disease at the time of study. All subjects filled in standardized questionnaires measuring HR-QoL. Disease control at the time of study was assessed by local IGF1 SDS.Results: IGF1 SDS were slightly higher in patients treated with SSTA in comparison with patients without use of SSTA (0.85 +/- 1.52 vs 0.25 +/- 1.21, P = 0.026), but the percentage of patients with insufficient control (IGF1 SDS >2) was not different (17 vs 9%, P = 0.208). Patients using SSTA reported poorer scores on most subscales of the RAND-36 and the acromegaly QoL and on all subscales of the multidimensional fatigue inventory-20. A subgroup analysis in patients with similar IGF1 levels (SSTA+, n = 26, IGF1 SDS 0.44 +/- 0.72 vs SSTA-, n = 44, IGF1 SDS 0.41 +/- 0.65) revealed worse scores on physical functioning, physical fatigue, reduced activity, vitality, and general health perception across all HR-QoL questionnaires in patients treated with SSTA.Conclusion: QoL is impaired in association with the need for prolonged postoperative therapy by SSTA in patients with acromegaly despite similar IGF1 levels.

KW - GROWTH-FACTOR-I

KW - LONG-TERM

KW - QUESTIONNAIRE ACROQOL

KW - LANREOTIDE TREATMENT

KW - DEPRESSION SCALE

KW - HOSPITAL ANXIETY

KW - DISEASE-ACTIVITY

KW - FOLLOW-UP

KW - HORMONE

KW - RADIOTHERAPY

U2 - 10.1530/EJE-11-0853

DO - 10.1530/EJE-11-0853

M3 - Article

C2 - 22250074

VL - 166

SP - 585

EP - 592

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 4

ER -

ID: 2442279